Candel Therapeutics Ownership 2024 | Who Owns Candel Therapeutics Now?
Institutional Ownership
20.42%
Insider Ownership
33.27%
Retail Ownership
46.31%
Institutional Holders
49.00
Candel Therapeutics Institutional Shareholders
Institutional Shareholders by % of Total Shares
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
NORTHPOND VENTURES, LLC | 6.63% | 21.71% | 1,935,215 | - | - | 11,998,333 | Jun 30, 2024 |
BLACKROCK INC. | 2.82% | 0.00% | 823,071 | 775,491 | 1629.87% | 5,103,040 | Jun 30, 2024 |
VANGUARD GROUP INC | 2.80% | 0.00% | 818,550 | 277,255 | 51.22% | 5,075,010 | Jun 30, 2024 |
STATE STREET CORP | 1.62% | 0.00% | 472,798 | 445,198 | 1613.04% | 2,931,348,000 | Jun 30, 2024 |
SANDS CAPITAL VENTURES, LLC | 1.39% | 0.84% | 405,837 | -405,900 | -50.00% | 2,516,189 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 1.36% | 0.00% | 397,886 | 252,180 | 173.07% | 2,467,401 | Jun 30, 2024 |
NUVEEN ASSET MANAGEMENT, LLC | 1.31% | 0.00% | 382,188 | 382,188 | 100.00% | 2,369,566 | Jun 30, 2024 |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.28% | 0.01% | 80,595 | -2,000 | -2.42% | 499,689 | Jun 30, 2024 |
MML INVESTORS SERVICES, LLC | 0.25% | 0.00% | 73,376 | 73,376 | 100.00% | 455,000 | Jun 30, 2024 |
BANK OF AMERICA CORP /DE/ | 0.19% | - | 54,449 | 54,449 | 100.00% | 337,584 | Jun 30, 2024 |
BANK OF NEW YORK MELLON CORP | 0.19% | 0.00% | 54,449 | 54,449 | 100.00% | 337,583 | Jun 30, 2024 |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.16% | 0.00% | 46,777 | 46,777 | 100.00% | 290,017 | Jun 30, 2024 |
NORTHERN TRUST CORP | 0.15% | - | 43,445 | 23,938 | 122.71% | 269,359,000 | Jun 30, 2024 |
CUBIST SYSTEMATIC STRATEGIES, LLC | 0.09% | 0.00% | 26,121 | 26,121 | 100.00% | 161,950 | Jun 30, 2024 |
ADVISOR GROUP HOLDINGS, INC. | 0.09% | 0.00% | 25,800 | 25,800 | 100.00% | 159,960 | Jun 30, 2024 |
RHUMBLINE ADVISERS | 0.08% | 0.00% | 22,985 | 22,985 | 100.00% | 142,501 | Jun 30, 2024 |
VIRTU FINANCIAL LLC | 0.08% | 0.01% | 22,639 | 22,639 | 100.00% | 140,000 | Jun 30, 2024 |
VONTOBEL HOLDING LTD. | 0.08% | 0.00% | 22,000 | 22,000 | 100.00% | 136,400 | Jun 30, 2024 |
SCHONFELD STRATEGIC ADVISORS LLC | 0.07% | 0.00% | 21,452 | 21,452 | 100.00% | 133,002 | Jun 30, 2024 |
RENAISSANCE TECHNOLOGIES LLC | 0.07% | 0.00% | 20,600 | -36,305 | -63.80% | 127,720 | Jun 30, 2024 |
Candel Therapeutics's largest institutional shareholder is NORTHPOND VENTURES, LLC, holding 6.63% of the company's total share outstanding, currently valued at $12.00M. The top 10 institutional shareholders own together 18.65% of the company.
Institutional Shareholders by % of Total Assets
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
NORTHPOND VENTURES, LLC | 6.63% | 21.71% | 1,935,215 | - | - | 11,998,333 | Jun 30, 2024 |
SANDS CAPITAL VENTURES, LLC | 1.39% | 0.84% | 405,837 | -405,900 | -50.00% | 2,516,189 | Jun 30, 2024 |
ALPINE GLOBAL MANAGEMENT, LLC | 0.06% | 0.02% | 18,761 | 18,761 | 100.00% | 116,318 | Jun 30, 2024 |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.28% | 0.01% | 80,595 | -2,000 | -2.42% | 499,689 | Jun 30, 2024 |
VIRTU FINANCIAL LLC | 0.08% | 0.01% | 22,639 | 22,639 | 100.00% | 140,000 | Jun 30, 2024 |
MML INVESTORS SERVICES, LLC | 0.25% | 0.00% | 73,376 | 73,376 | 100.00% | 455,000 | Jun 30, 2024 |
CUBIST SYSTEMATIC STRATEGIES, LLC | 0.09% | 0.00% | 26,121 | 26,121 | 100.00% | 161,950 | Jun 30, 2024 |
POINT72 (DIFC) LTD | 0.02% | 0.00% | 4,927 | 4,927 | 100.00% | 30,547 | Jun 30, 2024 |
POINT72 ASIA (SINGAPORE) PTE. LTD. | 0.00% | 0.00% | 813 | 813 | 100.00% | 5,041 | Jun 30, 2024 |
SCHONFELD STRATEGIC ADVISORS LLC | 0.07% | 0.00% | 21,452 | 21,452 | 100.00% | 133,002 | Jun 30, 2024 |
NUVEEN ASSET MANAGEMENT, LLC | 1.31% | 0.00% | 382,188 | 382,188 | 100.00% | 2,369,566 | Jun 30, 2024 |
VONTOBEL HOLDING LTD. | 0.08% | 0.00% | 22,000 | 22,000 | 100.00% | 136,400 | Jun 30, 2024 |
AMERITAS INVESTMENT PARTNERS, INC. | 0.01% | 0.00% | 1,941 | 1,941 | 100.00% | 12,034 | Jun 30, 2024 |
ADVISOR GROUP HOLDINGS, INC. | 0.09% | 0.00% | 25,800 | 25,800 | 100.00% | 159,960 | Jun 30, 2024 |
COREBRIDGE FINANCIAL, INC. | 0.04% | 0.00% | 10,660 | 10,660 | 100.00% | 66,199 | Jun 30, 2024 |
JANNEY MONTGOMERY SCOTT LLC | 0.04% | 0.00% | 11,615 | 11,615 | 100.00% | 72,000 | Jun 30, 2024 |
RENAISSANCE TECHNOLOGIES LLC | 0.07% | 0.00% | 20,600 | -36,305 | -63.80% | 127,720 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 1.36% | 0.00% | 397,886 | 252,180 | 173.07% | 2,467,401 | Jun 30, 2024 |
NEW YORK STATE COMMON RETIREMENT FUND | 0.06% | 0.00% | 17,000 | 17,000 | 100.00% | 105,000 | Jun 30, 2024 |
RHUMBLINE ADVISERS | 0.08% | 0.00% | 22,985 | 22,985 | 100.00% | 142,501 | Jun 30, 2024 |
The largest Candel Therapeutics shareholder by % of total assets is NORTHPOND VENTURES, LLC. The company owns 1.94M shares of Candel Therapeutics (CADL), representing 21.71% of its total assets.
Institutional Buyers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
BLACKROCK INC. | 2.82% | 0.00% | 823,071 | 775,491 | 1629.87% | 5,103,040 | Jun 30, 2024 |
STATE STREET CORP | 1.62% | 0.00% | 472,798 | 445,198 | 1613.04% | 2,931,348,000 | Jun 30, 2024 |
NUVEEN ASSET MANAGEMENT, LLC | 1.31% | 0.00% | 382,188 | 382,188 | 100.00% | 2,369,566 | Jun 30, 2024 |
VANGUARD GROUP INC | 2.80% | 0.00% | 818,550 | 277,255 | 51.22% | 5,075,010 | Jun 30, 2024 |
GEODE CAPITAL MANAGEMENT, LLC | 1.36% | 0.00% | 397,886 | 252,180 | 173.07% | 2,467,401 | Jun 30, 2024 |
MML INVESTORS SERVICES, LLC | 0.25% | 0.00% | 73,376 | 73,376 | 100.00% | 455,000 | Jun 30, 2024 |
BANK OF AMERICA CORP /DE/ | 0.19% | - | 54,449 | 54,449 | 100.00% | 337,584 | Jun 30, 2024 |
BANK OF NEW YORK MELLON CORP | 0.19% | 0.00% | 54,449 | 54,449 | 100.00% | 337,583 | Jun 30, 2024 |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.16% | 0.00% | 46,777 | 46,777 | 100.00% | 290,017 | Jun 30, 2024 |
CUBIST SYSTEMATIC STRATEGIES, LLC | 0.09% | 0.00% | 26,121 | 26,121 | 100.00% | 161,950 | Jun 30, 2024 |
ADVISOR GROUP HOLDINGS, INC. | 0.09% | 0.00% | 25,800 | 25,800 | 100.00% | 159,960 | Jun 30, 2024 |
NORTHERN TRUST CORP | 0.15% | - | 43,445 | 23,938 | 122.71% | 269,359,000 | Jun 30, 2024 |
RHUMBLINE ADVISERS | 0.08% | 0.00% | 22,985 | 22,985 | 100.00% | 142,501 | Jun 30, 2024 |
VIRTU FINANCIAL LLC | 0.08% | 0.01% | 22,639 | 22,639 | 100.00% | 140,000 | Jun 30, 2024 |
VONTOBEL HOLDING LTD. | 0.08% | 0.00% | 22,000 | 22,000 | 100.00% | 136,400 | Jun 30, 2024 |
SCHONFELD STRATEGIC ADVISORS LLC | 0.07% | 0.00% | 21,452 | 21,452 | 100.00% | 133,002 | Jun 30, 2024 |
MORGAN STANLEY | 0.07% | - | 19,458 | 19,458 | 100.00% | 120,640 | Jun 30, 2024 |
JPMORGAN CHASE & CO | 0.07% | - | 19,358 | 19,137 | 8659.28% | 120,020 | Jun 30, 2024 |
ALPINE GLOBAL MANAGEMENT, LLC | 0.06% | 0.02% | 18,761 | 18,761 | 100.00% | 116,318 | Jun 30, 2024 |
GOLDMAN SACHS GROUP INC | 0.06% | - | 18,225 | 18,225 | 100.00% | 112,995 | Jun 30, 2024 |
As of Jun 30 2024, Candel Therapeutics's largest institutional buyer is BLACKROCK INC.. The company purchased 775.49K stocks of CADL, valued at $5.10M.
Institutional Sellers
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
SANDS CAPITAL VENTURES, LLC | 1.39% | 0.84% | 405,837 | -405,900 | -50.00% | 2,516,189 | Jun 30, 2024 |
RENAISSANCE TECHNOLOGIES LLC | 0.07% | 0.00% | 20,600 | -36,305 | -63.80% | 127,720 | Jun 30, 2024 |
MARINER, LLC | - | - | - | -33,480 | -100.00% | - | Jun 30, 2024 |
RESOURCES INVESTMENT ADVISORS, LLC. | - | - | - | -29,783 | -100.00% | - | Jun 30, 2024 |
TRAPHAGEN INVESTMENT ADVISORS LLC | - | - | - | -17,215 | -100.00% | - | Jun 30, 2024 |
COMMONWEALTH EQUITY SERVICES, LLC | - | - | - | -14,182 | -100.00% | - | Jun 30, 2024 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -13,409 | -100.00% | - | Jun 30, 2024 |
TOWER RESEARCH CAPITAL LLC (TRC) | 0.00% | 0.00% | 1,252 | -2,450 | -66.18% | 7,762 | Jun 30, 2024 |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.28% | 0.01% | 80,595 | -2,000 | -2.42% | 499,689 | Jun 30, 2024 |
QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -1 | -100.00% | - | Jun 30, 2024 |
NORTHPOND VENTURES, LLC | 6.63% | 21.71% | 1,935,215 | - | - | 11,998,333 | Jun 30, 2024 |
DEUTSCHE BANK AG\ | 0.00% | - | 68 | 68 | 100.00% | 422 | Jun 30, 2024 |
AMALGAMATED BANK | 0.00% | - | 686 | 686 | 100.00% | 4,000 | Jun 30, 2024 |
POINT72 ASIA (SINGAPORE) PTE. LTD. | 0.00% | 0.00% | 813 | 813 | 100.00% | 5,041 | Jun 30, 2024 |
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 0.00% | - | 1,436 | 1,436 | 100.00% | 8,903 | Jun 30, 2024 |
AMERITAS INVESTMENT PARTNERS, INC. | 0.01% | 0.00% | 1,941 | 1,941 | 100.00% | 12,034 | Jun 30, 2024 |
LEGAL & GENERAL GROUP PLC | 0.01% | - | 2,197 | 2,197 | 100.00% | 13,621 | Jun 30, 2024 |
ROYAL BANK OF CANADA | 0.01% | - | 2,264 | 2,264 | 100.00% | 15,000 | Jun 30, 2024 |
POINT72 (DIFC) LTD | 0.02% | 0.00% | 4,927 | 4,927 | 100.00% | 30,547 | Jun 30, 2024 |
SIMPLEX TRADING, LLC | 0.02% | - | 5,001 | 5,001 | 100.00% | 31,000 | Jun 30, 2024 |
As of Jun 30 2024, Candel Therapeutics's biggest institutional seller is SANDS CAPITAL VENTURES, LLC. The company sold -0.41M shares of CADL, valued at $2.52M.
Institutional New positions
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
NUVEEN ASSET MANAGEMENT, LLC | 1.31% | 0.00% | 382,188 | 382,188 | 100.00% | 2,369,566 | Jun 30, 2024 |
MML INVESTORS SERVICES, LLC | 0.25% | 0.00% | 73,376 | 73,376 | 100.00% | 455,000 | Jun 30, 2024 |
BANK OF NEW YORK MELLON CORP | 0.19% | 0.00% | 54,449 | 54,449 | 100.00% | 337,583 | Jun 30, 2024 |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.16% | 0.00% | 46,777 | 46,777 | 100.00% | 290,017 | Jun 30, 2024 |
CUBIST SYSTEMATIC STRATEGIES, LLC | 0.09% | 0.00% | 26,121 | 26,121 | 100.00% | 161,950 | Jun 30, 2024 |
ADVISOR GROUP HOLDINGS, INC. | 0.09% | 0.00% | 25,800 | 25,800 | 100.00% | 159,960 | Jun 30, 2024 |
RHUMBLINE ADVISERS | 0.08% | 0.00% | 22,985 | 22,985 | 100.00% | 142,501 | Jun 30, 2024 |
VIRTU FINANCIAL LLC | 0.08% | 0.01% | 22,639 | 22,639 | 100.00% | 140,000 | Jun 30, 2024 |
SCHONFELD STRATEGIC ADVISORS LLC | 0.07% | 0.00% | 21,452 | 21,452 | 100.00% | 133,002 | Jun 30, 2024 |
MORGAN STANLEY | 0.07% | - | 19,458 | 19,458 | 100.00% | 120,640 | Jun 30, 2024 |
ALPINE GLOBAL MANAGEMENT, LLC | 0.06% | 0.02% | 18,761 | 18,761 | 100.00% | 116,318 | Jun 30, 2024 |
GOLDMAN SACHS GROUP INC | 0.06% | - | 18,225 | 18,225 | 100.00% | 112,995 | Jun 30, 2024 |
MILLENNIUM MANAGEMENT LLC | 0.06% | - | 17,344 | 17,344 | 100.00% | 107,533 | Jun 30, 2024 |
NEW YORK STATE COMMON RETIREMENT FUND | 0.06% | 0.00% | 17,000 | 17,000 | 100.00% | 105,000 | Jun 30, 2024 |
SQUAREPOINT OPS LLC | 0.04% | 0.00% | 12,238 | 12,238 | 100.00% | 75,876 | Jun 30, 2024 |
JANNEY MONTGOMERY SCOTT LLC | 0.04% | 0.00% | 11,615 | 11,615 | 100.00% | 72,000 | Jun 30, 2024 |
ALLIANCEBERNSTEIN L.P. | 0.04% | - | 10,660 | 10,660 | 100.00% | 66,092 | Jun 30, 2024 |
COREBRIDGE FINANCIAL, INC. | 0.04% | 0.00% | 10,660 | 10,660 | 100.00% | 66,199 | Jun 30, 2024 |
BARCLAYS PLC | 0.02% | - | 6,717 | 6,717 | 100.00% | 42,000 | Jun 30, 2024 |
SIMPLEX TRADING, LLC | 0.02% | - | 5,001 | 5,001 | 100.00% | 31,000 | Jun 30, 2024 |
POINT72 (DIFC) LTD | 0.02% | 0.00% | 4,927 | 4,927 | 100.00% | 30,547 | Jun 30, 2024 |
ROYAL BANK OF CANADA | 0.01% | - | 2,264 | 2,264 | 100.00% | 15,000 | Jun 30, 2024 |
LEGAL & GENERAL GROUP PLC | 0.01% | - | 2,197 | 2,197 | 100.00% | 13,621 | Jun 30, 2024 |
AMERITAS INVESTMENT PARTNERS, INC. | 0.01% | 0.00% | 1,941 | 1,941 | 100.00% | 12,034 | Jun 30, 2024 |
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 0.00% | - | 1,436 | 1,436 | 100.00% | 8,903 | Jun 30, 2024 |
POINT72 ASIA (SINGAPORE) PTE. LTD. | 0.00% | 0.00% | 813 | 813 | 100.00% | 5,041 | Jun 30, 2024 |
AMALGAMATED BANK | 0.00% | - | 686 | 686 | 100.00% | 4,000 | Jun 30, 2024 |
DEUTSCHE BANK AG\ | 0.00% | - | 68 | 68 | 100.00% | 422 | Jun 30, 2024 |
Candel Therapeutics's largest new institutional shareholder by number of shares is NUVEEN ASSET MANAGEMENT, LLC, purchased 382.19K shares, valued at $2.37M, as of undefined.
Institutional Sold Out
Name | % Total Shares | % Total Assets | Current Shares | Change Amount | Change % | Market Value | Date |
---|---|---|---|---|---|---|---|
MARINER, LLC | - | - | - | -33,480 | -100.00% | - | Jun 30, 2024 |
RESOURCES INVESTMENT ADVISORS, LLC. | - | - | - | -29,783 | -100.00% | - | Jun 30, 2024 |
TRAPHAGEN INVESTMENT ADVISORS LLC | - | - | - | -17,215 | -100.00% | - | Jun 30, 2024 |
COMMONWEALTH EQUITY SERVICES, LLC | - | - | - | -14,182 | -100.00% | - | Jun 30, 2024 |
TWO SIGMA INVESTMENTS, LP | - | - | - | -13,409 | -100.00% | - | Jun 30, 2024 |
QUBE RESEARCH & TECHNOLOGIES LTD | - | - | - | -1 | -100.00% | - | Jun 30, 2024 |
Candel Therapeutics's largest sold out institutional shareholder by shares sold is MARINER, LLC, sold -33.48K shares, valued at -, as of undefined.
Candel Therapeutics Mutual Fund Holders
Name | % Total Assets | Total Shares | Change Amount | Change % | Date |
---|---|---|---|---|---|
FRANKLIN STRATEGIC SERIES | 0.05% | 383,376 | - | - | Jan 31, 2024 |
BRIDGEWAY FUNDS INC | 0.03% | 74,895 | -50,000 | -40.03% | Mar 28, 2024 |
FIDELITY SELECT PORTFOLIOS | 0.00% | 133,104 | -165,280 | -55.39% | Feb 29, 2024 |
VANGUARD INDEX FUNDS | 0.00% | 541,295 | -21,275 | -3.78% | Mar 31, 2024 |
FIDELITY CONCORD STREET TRUST | 0.00% | 138,080 | 5,886 | 4.45% | Feb 29, 2024 |
VANGUARD INSTITUTIONAL INDEX FUNDS | 0.00% | 1,723 | - | - | Mar 31, 2024 |
PROSHARES TRUST | 0.00% | 2,430 | - | - | Feb 29, 2024 |
USAA MUTUAL FUNDS TRUST | 0.00% | 1,741 | - | - | Jan 31, 2024 |
VANGUARD SCOTTSDALE FUNDS | 0.00% | 5,669 | - | - | Feb 29, 2024 |
EQ ADVISORS TRUST | 0.00% | 3,108 | - | - | Mar 31, 2024 |
iSHARES TRUST | 0.00% | 42,801 | -1,128 | -2.57% | Mar 31, 2024 |
Invesco Exchange-Traded Fund Trust II | 0.00% | 533 | - | - | Jan 31, 2024 |
JOHN HANCOCK VARIABLE INSURANCE TRUST | 0.00% | 599 | - | - | Mar 31, 2024 |
Candel Therapeutics's largest mutual fund holder by % of total assets is "FRANKLIN STRATEGIC SERIES", owning 383.38K shares, compromising 0.05% of its total assets.
Candel Therapeutics Institutional Ownership Trends
Institutional Holdings Trend
Date | Holdings | Change % |
---|---|---|
30 Jun, 24 | 49 | 157.89% |
31 Mar, 24 | 19 | -9.52% |
31 Dec, 23 | 21 | 10.53% |
30 Sep, 23 | 19 | - |
30 Jun, 23 | 19 | -5.00% |
31 Mar, 23 | 20 | - |
31 Dec, 22 | 20 | -13.04% |
30 Sep, 22 | 23 | 9.52% |
30 Jun, 22 | 21 | -4.55% |
31 Mar, 22 | 22 | 10.00% |
31 Dec, 21 | 20 | 66.67% |
30 Sep, 21 | 12 | - |
As of 30 Jun 24, 49 institutions are holding Candel Therapeutics's shares, representing an increase of 157.89% compared to the previous quarter.
Shares Outstanding Trend
Date | Shares Outstanding | Change % |
---|---|---|
30 Jun, 24 | 5,961,761 | 57.71% |
31 Mar, 24 | 3,780,258 | -6.13% |
31 Dec, 23 | 4,027,160 | -23.41% |
30 Sep, 23 | 5,257,852 | -2.09% |
30 Jun, 23 | 5,370,044 | -1.98% |
31 Mar, 23 | 5,478,268 | 1.06% |
31 Dec, 22 | 5,420,630 | -10.86% |
30 Sep, 22 | 6,080,991 | -4.18% |
30 Jun, 22 | 6,345,954 | -4.92% |
31 Mar, 22 | 6,674,326 | -3.99% |
31 Dec, 21 | 6,951,803 | 42.33% |
30 Sep, 21 | 4,884,338 | - |
Candel Therapeutics (CADL) has 5.96M shares outstanding as of 30 Jun 24, up 57.71% compared to the previous quarter.
Institutional Ownership Trend
Date | Ownership % | Change % |
---|---|---|
30 Jun, 24 | 20.42% | 11.96% |
31 Mar, 24 | 13.06% | 6.74% |
31 Dec, 23 | 13.93% | 4.21% |
30 Sep, 23 | 18.18% | 5.27% |
30 Jun, 23 | 18.57% | 5.17% |
31 Mar, 23 | 18.94% | 5.38% |
31 Dec, 22 | 18.76% | 4.23% |
30 Sep, 22 | 21.05% | 4.34% |
30 Jun, 22 | 22.03% | 4.07% |
31 Mar, 22 | 23.26% | 2.62% |
31 Dec, 21 | 29.80% | 6.80% |
30 Sep, 21 | 20.94% | - |
As of 30 Jun 24, Candel Therapeutics is held by 20.42% institutional shareholders, representing a 11.96% growth compared to 31 Mar 24.
Institutional Increased Positions Trend
Date | Increased Positions | Change % |
---|---|---|
30 Jun, 24 | 42 | 366.67% |
31 Mar, 24 | 9 | - |
31 Dec, 23 | 9 | 50.00% |
30 Sep, 23 | 6 | 20.00% |
30 Jun, 23 | 5 | -28.57% |
31 Mar, 23 | 7 | -12.50% |
31 Dec, 22 | 8 | -11.11% |
30 Sep, 22 | 9 | 50.00% |
30 Jun, 22 | 6 | -40.00% |
31 Mar, 22 | 10 | -33.33% |
31 Dec, 21 | 15 | 25.00% |
30 Sep, 21 | 12 | - |
42 institutional shareholders have increased their position in CADL stock as of 30 Jun 24 compared to 9 in the previous quarter (a 366.67% increase).
Institutional Reduced Positions Trend
Date | Reduced Positions | Change % |
---|---|---|
30 Jun, 24 | 4 | -20.00% |
31 Mar, 24 | 5 | - |
31 Dec, 23 | 5 | - |
30 Sep, 23 | 5 | - |
30 Jun, 23 | 5 | 25.00% |
31 Mar, 23 | 4 | - |
31 Dec, 22 | 4 | 33.33% |
30 Sep, 22 | 3 | -57.14% |
30 Jun, 22 | 7 | 16.67% |
31 Mar, 22 | 6 | 500.00% |
31 Dec, 21 | 1 | - |
30 Sep, 21 | - | - |
4 institutional shareholders have reduced their position in CADL stock as of 30 Jun 24 compared to 5 in the previous quarter (a -20.00% decrease).
All Institutional Ownership Trend Data
Date | Holdings | Change % | Shares Outstanding | Change % | Ownership % | Change % | Increased Positions | Change % | Reduced Positions | Change % |
---|---|---|---|---|---|---|---|---|---|---|
30 Jun, 24 | 49 | 157.89% | 5,961,761 | 57.71% | 20.42% | 11.96% | 42 | 366.67% | 4 | -20.00% |
31 Mar, 24 | 19 | -9.52% | 3,780,258 | -6.13% | 13.06% | 6.74% | 9 | - | 5 | - |
31 Dec, 23 | 21 | 10.53% | 4,027,160 | -23.41% | 13.93% | 4.21% | 9 | 50.00% | 5 | - |
30 Sep, 23 | 19 | - | 5,257,852 | -2.09% | 18.18% | 5.27% | 6 | 20.00% | 5 | - |
30 Jun, 23 | 19 | -5.00% | 5,370,044 | -1.98% | 18.57% | 5.17% | 5 | -28.57% | 5 | 25.00% |
31 Mar, 23 | 20 | - | 5,478,268 | 1.06% | 18.94% | 5.38% | 7 | -12.50% | 4 | - |
31 Dec, 22 | 20 | -13.04% | 5,420,630 | -10.86% | 18.76% | 4.23% | 8 | -11.11% | 4 | 33.33% |
30 Sep, 22 | 23 | 9.52% | 6,080,991 | -4.18% | 21.05% | 4.34% | 9 | 50.00% | 3 | -57.14% |
30 Jun, 22 | 21 | -4.55% | 6,345,954 | -4.92% | 22.03% | 4.07% | 6 | -40.00% | 7 | 16.67% |
31 Mar, 22 | 22 | 10.00% | 6,674,326 | -3.99% | 23.26% | 2.62% | 10 | -33.33% | 6 | 500.00% |
31 Dec, 21 | 20 | 66.67% | 6,951,803 | 42.33% | 29.80% | 6.80% | 15 | 25.00% | 1 | - |
30 Sep, 21 | 12 | - | 4,884,338 | - | 20.94% | - | 12 | - | - | - |
Candel Therapeutics Insider Shareholders Trades
Open Market Insider Trades
Open Market Insider Buys
Date | Name | Relation | Role | Transaction | Buy/Sell | Shares | Price | Value | Shares Held | Source |
---|
Insider Sells
All Insider Owners Trades
The last insider sell of Candel Therapeutics's stock was made by Tyagarajan Seshu on Jul 19 2024, selling 14,851 shares at $6.47 per share (valued at $96.12K).
Candel Therapeutics Insider Ownership Trends
All Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q3 2024 | - | 10 | - |
Q2 2024 | 8 | - | - |
Q1 2024 | - | 4 | - |
Q4 2023 | 5 | 5 | 100.00% |
Q2 2023 | 14 | - | - |
Q4 2022 | 23 | - | - |
Q3 2022 | 7 | - | - |
Q2 2022 | 2 | 4 | 50.00% |
Q1 2022 | 4 | 2 | 200.00% |
Q4 2021 | - | 1 | - |
Q3 2021 | 17 | 28 | 60.71% |
Q4 2018 | - | - | - |
0 total buy trades, and 10 total sell trades (buy/sell ratio of 0.00%) were made by Candel Therapeutics's insiders, as of Q3 2024.
Open Market Insider Trades Trend
Date | Buy | Sell | Buy/Sell Ratio |
---|---|---|---|
Q3 2024 | - | 10 | - |
Q2 2024 | - | - | - |
Q1 2024 | - | - | - |
Q4 2023 | - | - | - |
Q2 2023 | - | - | - |
Q4 2022 | 13 | - | - |
Q3 2022 | - | - | - |
Q2 2022 | - | - | - |
Q1 2022 | - | - | - |
Q4 2021 | - | - | - |
Q3 2021 | 8 | - | - |
Q4 2018 | - | - | - |
As of Q3 2024, Insider owners conducted 0 open market buy trades and 10 open market sell trades of Candel Therapeutics's stocks.
Candel Therapeutics Peer Ownership
Ticker | Company |
---|---|
ENOB | Renovaro Biosciences Inc. |
PMVP | PMV Pharmaceuticals, Inc. |
MNPR | Monopar Therapeutics Inc. |
OKYO | OKYO Pharma Limited |
MLYS | Mineralys Therapeutics, Inc. |
AVTE | Aerovate Therapeutics, Inc. |
ACRV | Acrivon Therapeutics, Inc. Common Stock |
ACXP | Acurx Pharmaceuticals, Inc. |
ANTX | AN2 Therapeutics, Inc. |
PHVS | Pharvaris N.V. |
RZLT | Rezolute, Inc. |
INDP | Indaptus Therapeutics, Inc. |
TPST | Tempest Therapeutics, Inc. |
PEPG | PepGen Inc. |
ANEB | Anebulo Pharmaceuticals, Inc. |
ADAG | Adagene Inc. |
MOLN | Molecular Partners AG |
FBRX | Forte Biosciences, Inc. |
CADL Ownership FAQ
Who Owns Candel Therapeutics?
Candel Therapeutics is owned by institutional shareholders (20.42%), insiders (33.27%), and public (46.31%). The largest institutional shareholder of Candel Therapeutics is NORTHPOND VENTURES, LLC (6.63% of total shares) and the top mutual fund owner is FRANKLIN STRATEGIC SERIES (0.05% of total shares).
Who are the major institutional shareholders of Candel Therapeutics?
Candel Therapeutics's major institutional shareholders are NORTHPOND VENTURES, LLC, BLACKROCK INC., VANGUARD GROUP INC, STATE STREET CORP, and SANDS CAPITAL VENTURES, LLC. The top five shareholders own together 15.26% of the company's share outstanding.
How many Candel Therapeutics shareholders are there?
As of Jun 2024, there are 49 institutional shareholders of Candel Therapeutics.
What percentage of Candel Therapeutics is owned by NORTHPOND VENTURES, LLC?
NORTHPOND VENTURES, LLC owns 1.94M shares of Candel Therapeutics, representing 6.63% of the company's total shares outstanding, valued at $12M (as of Jun 2024).
What percentage of Candel Therapeutics is owned by BLACKROCK INC?
As of Jun 2024, BLACKROCK INC holds 823.07K shares of Candel Therapeutics (CADL), compromising 2.82% of the company, valued at $5.1M.
What percentage of Candel Therapeutics is owned by VANGUARD GROUP INC?
VANGUARD GROUP INC is the third largest holder of Candel Therapeutics. The company owns 818.55K of the company's shares outstanding (worth $5.08M).